Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion type Assertion NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_head.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion description "[The marked cytoplasmic expression of PRMT5 was frequently observed in high-grade subtypes (1 of 17 low grade, 21 of 81 intermediate grade, and 25 of 32 high grade; P < .0001) such as solid adenocarcinoma with the low expression of thyroid transcription factor 1 (the master regulator of lung) and low expression of cytokeratin 7 and E-cadherin (2 markers for bronchial epithelial differentiation), whereas the high nuclear expression of PRMT5 was frequently noted in adenocarcinoma in situ, a low-grade subtype (6 of 17 low grade, 25 of 81 intermediate grade, and 3 of 32 high grade; P = .0444).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_provenance.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion evidence source_evidence_literature NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_provenance.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion SIO_000772 24775604 NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_provenance.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion wasDerivedFrom befree-2016 NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_provenance.
- NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_assertion wasGeneratedBy ECO_0000203 NP1177366.RAvI0Zq5n87jWnIeUlyDBu9dQviDd1G4rOkTw2KYbYxpM130_provenance.